Sarepta Therapeutics
S&P 600
$20.45
-0.34%
Delayed · cached 15 min
Fair value analysis
Reported earnings per share are negative or zero, so the earnings-based models cannot produce a value.
Financial DNA score 12 / 100
Educational data only. Not a recommendation to buy, sell or hold any security.